BACKGROUND: Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. METHODS: All serious adverse events that were cardiovascular thrombotic events were reviewed in 2434 patients with stage II or III colorectal cancer participating in a randomized, placebo-controlled trial of rofecoxib, 25 mg daily, starte...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record